辅助性帕克利珠单抗治疗利福平敏感肺结核:概念验证、部分随机、双盲、安慰剂对照、剂量递增试验
在利福平敏感肺结核患者中评估辅助性帕克利珠单抗(人源化抗IL-4单抗)的安全性与疗效。研究采用部分随机、双盲、安慰剂对照、剂量递增设计,未发现与研究药物相关的4级或严重不良事件;随机队列第8周痰培养阳性时间(TTP)中位数在帕克利珠单抗组与安慰剂组均为42天(P=0.185),但帕克利珠单抗组TTP增加速率更大。
要点
- 帕克利珠单抗在利福平敏感肺结核患者中未发现与研究药物相关的4级或严重不良事件。
- 随机队列第8周痰培养TTP中位数帕克利珠单抗组与安慰剂组均为42天(P=0.185)。
- 帕克利珠单抗组TTP增加速率较安慰剂组高0.011 log10 TTP/天(95%贝叶斯可信区间0.006至0.015)。
核心结论
- 无证据表明阻断IL-4不安全,初步疗效结果与动物模型一致,支持在更大规模2期试验中进一步研究辅助性抗IL-4干预治疗结核病。
研究设计与样本
- 利福平敏感肺结核患者接受单次静脉输注帕克利珠单抗或安慰剂,并接受标准6个月结核治疗。
- 帕克利珠单抗剂量在连续队列中递增:队列1非随机0.05 mg/kg(n=4);队列2非随机0.5 mg/kg(n=4);队列3随机2.5 mg/kg(n=9)或安慰剂(n=3);队列4随机10 mg/kg(n=9)或安慰剂(n=3)。
- 共同主要安全性结局为所有队列(1-4)中与研究药物相关的4级或严重不良事件(G4/SAE)。
- 共同主要疗效结局为随机队列(3-4)合并的第8周痰培养阳性时间(TTP)。
主要发现
- 队列3-4中78%-100%的参与者帕克利珠单抗水平超过IL-4 50%中和剂量达8周。
- 未发生与研究药物相关的G4/SAE。
- 第8周TTP中位数在帕克利珠单抗组与安慰剂组均为42天(P=0.185)。
- 帕克利珠单抗组TTP增加速率较安慰剂组高0.011 log10 TTP/天(95%贝叶斯可信区间0.006至0.015 log10 TTP/天)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Interleukin 4 (IL-4), increased in tuberculosis infection, may impair bacterial killing. Blocking IL-4 confers benefit in animal models. We evaluated safety and efficacy of pascolizumab (humanized anti-IL-4 monoclonal antibody) as adjunctive tuberculosis treatment. METHODS: Participants with rifampicin-susceptible pulmonary tuberculosis received a single intravenous infusion of pascolizumab or placebo, and standard 6-month tuberculosis treatment. Pascolizumab dose increased in successive cohorts: (1) nonrandomized 0.05 mg/kg (n = 4); (2) nonrandomized 0.5 mg/kg (n = 4); (3) randomized 2.5 mg/kg (n = 9) or placebo (n = 3); and (4) randomized 10 mg/kg (n = 9) or placebo (n = 3). Coprimary safety outcome was study-drug-related grade 4 or serious adverse event (G4/SAE) in all cohorts (1-4). Coprimary efficacy outcome was week 8 sputum culture time-to-positivity (TTP) in randomized cohorts (3-4) combined. RESULTS: Pascolizumab levels exceeded IL-4 50% neutralizing dose for 8 weeks in 78%-100% of participants in cohorts 3-4. There were no study-drug-related G4/SAEs. Median week-8 TTP was 42 days in pascolizumab and placebo groups (P = .185). Rate of TTP increase was greater with pascolizumab (difference from placebo 0.011 log10 TTP/day; 95% Bayesian credible interval 0.006 to 0.015 log10 TTP/day). CONCLUSIONS: There was no evidence to suggest blocking IL-4 was unsafe. Preliminary efficacy findings are consistent with animal models. This supports further investigation of adjunctive anti-IL-4 interventions for tuberculosis in larger phase 2 trials. CLINICAL TRIALS REGISTRATION: NCT01638520.
引用
- Paton NI, Gurumurthy M, Lu Q, et al. Adjunctive Pascolizumab in Rifampicin-Susceptible Pulmonary Tuberculosis: Proof-of-Concept, Partially-Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Trial. J Infect Dis. 2024. PMID: 38527849. doi:10.1093/infdis/jiae104
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。